Information The 2022 Life Science Intellectual Property Forum Challenges and Prospects for Solutions in the Innovation Ecosystem Found in the COVID-19 Pandemic
The 2022 Life Science IP Forum will be held on Friday, February 18, 2022 at 1:00 p.m. via online seminar.
The spread of the novel coronavirus infection (COVID-19) has had a serious impact on the lives and livelihoods of people around the world. Against this backdrop, the "2021 Life Science IP Forum" will discuss what mechanisms should be used to protect IP rights as a driver of the R&D innovation cycle and the use of IP rights for access to medicines to solve life-threatening situations in response to pandemics, including COVID-19. Representatives from industry, academia, and government crossed boundaries to discuss how to strike a balance.
The Pharmaceutical Manufacturers Association of Japan (PMAJ) recognizes that, in the midst of the worldwide spread of novel coronavirus infections, the promotion of rapid research and development of effective and safe therapeutic drugs and vaccines is an important means toward convergence, and its member companies are committed to this and will work together to promote innovation, including diversion of existing drugs (drug repositioning), creation of vaccines and new therapeutic drugs. In addition to promoting innovation such as the diversion of existing drugs (drug repositioning), the creation of vaccines, and the creation of new therapeutic agents, member companies are also engaged in industry-academia-government collaboration.
On the other hand, given the current situation in which domestically produced vaccine R&D has fallen behind Western companies, the "2021 Life Science IP Forum" also pointed out the need from the perspective of national security to promote measures against infectious diseases from peacetime to enable a rapid response to a pandemic.
In the "2022 Life Science IP Forum," in order to accelerate the creation of domestically produced COVID-19 vaccines and therapeutics, in addition to contingency measures such as clinical trials, approval systems, and assurance of business feasibility, the forum discussed the following issues in order to create innovation that will lead to the creation of vaccines and therapeutics for infectious diseases, from basic to applied research Representatives from industry, academia, and government will cross the boundaries to discuss what kind of social infrastructure should be implemented from normal times, including how research support should be provided in normal times and what kind of system for promoting translational research, including venture development and industry-academia collaboration, should be implemented in normal times.
